徐诺药业研究院成功设计了一系列强效RET激酶抑制剂
08/20/2019 新闻 admin

美国北卡罗利市和中国上海市 2019年8月16日/(GLOBE NEWSWIRE)-

致力于抗肿瘤新药开发的中美跨国制药公司徐诺药业(股票代码:XYNO)今日宣布徐诺药业研究院(XRI)通过计算机辅助药物设计成功设计了一系列强效RET激酶抑制剂。RET(“Rearranged during transfection”)是一种受体酪氨酸激酶,可激活涉及细胞增殖和存活的多个下游通路。RET融合可导致发生包括非小细胞肺癌、乳头状甲状腺癌和甲状腺髓样癌等多种肿瘤。

徐诺药业的RET激酶抑制剂是一类具有新颖和稳定结构的乙炔衍生物。初步活性测试显示对TT肿瘤细胞表现出突出和选择性的抑制活性,并且测得候选化合物的IC50值在中等至低纳摩尔范围内。
“徐诺研究院专注于开发创新的肿瘤治疗候选药物。我们最近升级了研究设备和设施,并聘请了更多的科学家。我们相信徐诺研究院有能力并高效地设计和合成强效的药物分子。”徐诺药业董事长兼首席执行官徐英霖先生评论道。

徐诺药业自主研发的临床前候选药物XP-103和XP-104已于2018年申请专利。XP-103是原肌球蛋白受体激酶(TRK)和Fra-1酶的双重抑制剂。XP-104是一个RET抑制剂,正在开发用于治疗多种类型肿瘤,尤其是对其他靶向疗法耐药的肿瘤。XP-104的动物研究即将启动。

关于徐诺药业

徐诺药业是一家专注于肿瘤药物开发的生物制药公司。徐诺药业目前的产品管线主要包括三款候选药物,艾贝司他、 XP-105 和 XP-102。公司拥有这些药物的全球独家开发、生产和商业化权益。其领先的候选药物艾贝司他正在进行治疗肾细胞癌(与培唑帕尼联用)和单药治疗非霍奇金淋巴瘤的全球关键临床试验。徐诺药业另外一款临床阶段候选药物为可进入临床2期的XP-105(BI 860585),这是一个ATP竞争性的mTORC1 / 2抑制剂,对多种实体瘤有效。徐诺药业的临床前候选药物XP-102(BI 882370)是一个泛-RAF抑制剂。
投资者关系、媒体和商务拓展请联系:
angela.feng@xynomicpharma.com

Use of Forward-Looking Statements
This press release contains “forward-looking” statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Xynomic has based these forward-looking statements largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related Xynomic’s financial position and need for additional capital to complete the planned trials and support its continuing operation, risks related to uncertainty in maintaining and obtaining regulatory approval and ultimately commercialize its drug candidates or delays in doing so; and the risks more fully described in Xynomic’s filings that Xynomic may make with the SEC in the future. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.